Compare AMETEK, Inc. (AME) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMETEK, Inc. vs Davita Inc — how do they compare? AMETEK, Inc. trades at $235.14 (market cap $53.63B), while Davita Inc trades at $233.6 (market cap $14.94B). The key difference: AMETEK, Inc. is far larger — about 3.6× Davita Inc's market cap, and AMETEK, Inc. pays a 0.58% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| AME | DVA | |
|---|---|---|
Market Cap | $53.63B | $14.94B |
Sector | Industrials | Health |
52-Week High | $241.94 | $235.71 |
52-Week Low | $176.44 | $103.87 |
Enterprise Value | $55.33B | $27.50B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AME trades at $233.98, up 0.42% today, with a neutral technical signal and strong fundamentals including three consecutive quarterly EPS beats. The company maintains robust profitability with a 20.11% net margin and recently completed the acquisition of First Aviation Services, expanding its aerospace and defense footprint. Cash flow remains positive with $83.95M net inflow in 2025.
Outlook is positive with a $260 consensus price target representing 11% upside, supported by 68.97% analyst buy ratings. Risks include elevated P/E of 35.34 and integration challenges from recent acquisitions. The stock offers growth exposure to industrial technology and aerospace sectors with stable dividend payments.
DaVita (DVA) trades at $232.80, up 1.45% on the day, with a bullish technical signal and strong institutional backing. Recent earnings show mixed quarterly beats, with Q1 2026 exceeding expectations. Revenue growth is steady, reaching $13.64B in 2025, though net income margin dipped to 5.47%. The stock is supported by positive analyst coverage and expansion in kidney care services, including AI-driven scheduling improvements. Current price sits near resistance at $233, with RSI levels indicating potential overbought conditions.
Outlook remains cautiously optimistic given DVA's market leadership and operational improvements, but high debt levels and valuation metrics pose risks. Analyst consensus suggests moderate upside to the $222.80 price target, with 39% buy ratings. Key risks include regulatory changes in healthcare and execution challenges in growth initiatives. The stock's proximity to yearly highs warrants monitoring for pullback opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMETEK, Inc.
Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.
Read more on AME →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
